American Journal of Cancer Research and Reviews


Hepatitis C Virus as risk factor for development of hepatocellular carcinoma in Egypt: II-Enhancement role of matrix metalloproteinases-2 in dissemination of HCC

Research Article of American Journal of Cancer Research and Reviews Hepatitis C Virus as risk factor for development of hepatocellular carcinoma in Egypt: II-Enhancement role of matrix metalloproteinases-2 in dissemination of HCC Laila H. El-Sayed1, Manal A. Nabil1, Salwa Nayer. M. A2, Saeid A. Oda3, Abdel Rahman M. A4 and Hossam M. Ghoneim1 1Departement of Immunology & Allergy-Medical Research Institute, Alexandria University; 2Departement of Cancer Management & Research- Medical Research Institute, Alexandria University; 3Departement of Internal Medicine-Medical Research Institute, Alexandria University; 4Departementof Clinical Pathology- Alexandria Military Academy Hospital Hepatitis C virus (HCV) infection is a major public health problem all over the world. Egypt has the highest prevalence of HCV worldwide (17-26%) with subsequent high morbidity from chronic liver disease, cirrhosis and hepatocellular carcinoma (HCC). Matrix metalloproteinase are proteolytic enzymes that play a role in the degradation of extracellular matrix (ECM) which is necessary for invasion and metastasis of tumor cells. The present work was designed to study the relationship between HCV infection and circulating MMP-2 level in chronic HCV patients (either without or with hepatic complication) and compared to that of non- HCV cirrhotic patients as well as healthy controls, in order to clarify the role of HCV in changing microenvironment and underlying mechanisms associated with dissemination of malignancy. The level of MMP-2 was estimated in sera collected at different stages of HCV infections as well as in ascetic fluids collected from those developing either HCC or cirrhosis. Statistical analysis of their results revealed that MMP-2 levels were significantly elevated in all patient groups as compared to healthy controls. The level of MMP-2 in HCV patients with HCC was significantly elevated when compared to other HCV patients. Meanwhile MMP-2 in ascetic fluids of cirrhotic patients were similar to that detected in their sera, while in HCC patients there were ...

Hepatitis C Virus as risk factor for development of hepatocellular carcinoma in Egypt: I- HCV promotes HCC progression by increasing cancer stem marker (CD133 and CD44) expression

Research Article of American Journal of Cancer Research and Reviews Hepatitis C Virus as risk factor for development of hepatocellular carcinoma in Egypt: I- HCV promotes HCC progression by increasing cancer stem marker (CD133 and CD44) expression Laila H. El-Sayed 1, Manal A. Nabil 1,  Salwa Nayer. M. A 2, Saeid A. Oda 3 , Abdel Rahman M. A 4and Hossam M. Ghoneim 1 1Departement of Immunology & Allergy-Medical Research Institute, Alexandria University 2Departement of Cancer Management & Research- Medical Research Institute, Alexandria University 3Departement of Internal Medicine-Medical Research Institute, Alexandria University 4Departementof Clinical Pathology- Alexandria Military Academy Hospital Hepatitis C virus (HCV) represents a major public health problem, affecting 3% of the world’s population. In majority of infected patients, HCV can effectively evade innate immunity resulting in chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma (HCC). Similar to most solid tumors, HCCs are believed to contain poorly differentiated cancer stem cell-like cells (CSCs) that initiate tumorigenesis and confer resistance to chemotherapy. The present work attempted to study the mRNA expression of cancer stem cell markers (CD133 and CD44) in patients with chronic hepatitis C virus (reflecting the role of HCV) and their correlation with progression toward cirrhosis and HCC. Peripheral blood mononuclear cell (PBMC) prepared from chronic HCV patients (either with or without complications) were probed for mRNA expression of CD133 and CD44 by RT-PCR and compared to that of non-HCV cirrhotic patients as well as healthy control subjects. Our results showed that mRNA expression of CD133 was significantly elevated in all HCV patients either with or without complications but not in those with non-HCV cirrhosis, with maximal expression in patients without complications (HCV patients only). On the other hand, maximal CD44 mRNA expression was recorded in HCC patients. Taken together, these results suggests that, chronic HCV ...

Manuscript Title: The title should be a brief phrase.

Author Information: List full names and affiliation of all authors, including Emails and phone numbers of corresponding author.

Abstract: The abstract should be less than 500 words. Following abstract, a list of keywords and abbreviations should be added. The keywords should be no more than 10. Abbreviation are only used for non standard and long terms.

Introduction: The introduction should included a clear statement of current problems.

Materials and Methods: This section should be clearly described.

Results and discussion: Authors may put results and discussion into a single section or show them separately.

Acknowledgement: This section includes a brief acknowledgment of people, grant details, funds

References: References should be listed in a numbered citation order at the end of the manuscript. DOIs and links to referenced articles should be added if available. Abstracts and talks for conferences or papers not yet accepted should not be cited. Examples Published Papers: 

1. Hongmei YANG. A study on the Management Mode of Modern Vocational Education in China. Global journal of Economics and Business Administration, 2018, 3: 10.DOI: 10.28933/gjeba-2018-07-2301 

Tables and figures: Tables should be used at a minimum with a short descriptive title. The preferred file formats for Figures/Graphics are GIF, TIFF, JPEG or PowerPoint.

Publication fees: We do not charge any submission charges, but authors are required to pay publication fees after their manuscripts are accepted for publication. For authors who receive our invitations, please send us the invitation code to receive the special discount.

Proofreading and Publication: A proof will be sent to the corresponding author before publication. Authors should carefully read the proof to avoid any errors and return the proof to the editorial office. Editorial office will publish the article shortly.

Withdrawal Policy: When you want to withdraw an article, please contact us. We will withdraw/retract it from our system after reviewing your request.

Terms of Use/Privacy Policy/Disclaimer/Other Policies: you agree that by using or receiving our services, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies.

About the journal
The journal is hosted by eSciPub LLC. Our aim is to provide a platform that encourages publication of the most recent research and reviews for authors from all countries.


About the publisher
eSciPub LLC is a publisher to support Open Access initiative located in Houston, Texas, USA. It is a member of the largest community of professional publishers in the United States: the Independent Book Publishers Association. It hosts more than 100 Open Access journals in Medicine, Business & Economics, Agriculture, Biological Sciences, Chemistry, Education, Physical Sciences, Sociology, and Engineering and Technology.


Rapid Response Team
Please feel free to contact our rapid response team if you have any questions. Our customer representative will answer your questions shortly.

American Journal of Cancer Research and Reviews

Loading